These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 18557724)
21. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study. Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962 [TBL] [Abstract][Full Text] [Related]
22. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. Mauiyyedi S; Pelle PD; Saidman S; Collins AB; Pascual M; Tolkoff-Rubin NE; Williams WW; Cosimi AB; Schneeberger EE; Colvin RB J Am Soc Nephrol; 2001 Mar; 12(3):574-582. PubMed ID: 11181806 [TBL] [Abstract][Full Text] [Related]
23. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Haas M Clin Nephrol; 2011 Apr; 75(4):271-8. PubMed ID: 21426880 [TBL] [Abstract][Full Text] [Related]
25. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189 [TBL] [Abstract][Full Text] [Related]
26. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Ali S; Ormsby A; Shah V; Segovia MC; Kantz KL; Skorupski S; Eisenbrey AB; Mahan M; Huang MA Transpl Immunol; 2012 Jan; 26(1):62-9. PubMed ID: 21907804 [TBL] [Abstract][Full Text] [Related]
27. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. Regele H; Böhmig GA; Habicht A; Gollowitzer D; Schillinger M; Rockenschaub S; Watschinger B; Kerjaschki D; Exner M J Am Soc Nephrol; 2002 Sep; 13(9):2371-80. PubMed ID: 12191982 [TBL] [Abstract][Full Text] [Related]
28. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738 [TBL] [Abstract][Full Text] [Related]
29. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant? Satoskar AA; Lehman AM; Nadasdy GM; Sedmak DD; Pesavento TE; Henry ML; Pelletier RP; Ferguson RM; Nadasdy T Clin Transplant; 2008; 22(1):61-7. PubMed ID: 18217907 [TBL] [Abstract][Full Text] [Related]
30. Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies. Herman J; Lerut E; Van Damme-Lombaerts R; Emonds MP; Van Damme B Transplantation; 2005 May; 79(10):1435-40. PubMed ID: 15912116 [TBL] [Abstract][Full Text] [Related]
31. Renal allograft pathology in the sensitized patient. Cornell LD Curr Opin Organ Transplant; 2013 Jun; 18(3):327-36. PubMed ID: 23619513 [TBL] [Abstract][Full Text] [Related]
32. The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses. Wasowska B; Baldwin WM; Howell DN; Sanfilippo F Transplantation; 1993 Sep; 56(3):672-80. PubMed ID: 7692630 [TBL] [Abstract][Full Text] [Related]
36. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785 [TBL] [Abstract][Full Text] [Related]
37. The role of C4d immunostaining in the evaluation of the causes of renal allograft dysfunction. Ranjan P; Nada R; Jha V; Sakhuja V; Joshi K Nephrol Dial Transplant; 2008 May; 23(5):1735-41. PubMed ID: 18065805 [TBL] [Abstract][Full Text] [Related]
38. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Loupy A; Hill GS; Suberbielle C; Charron D; Anglicheau D; Zuber J; Timsit MO; Duong JP; Bruneval P; Vernerey D; Empana JP; Jouven X; Nochy D; Legendre CH Am J Transplant; 2011 Jan; 11(1):56-65. PubMed ID: 21199348 [TBL] [Abstract][Full Text] [Related]
39. Emphysematous pyelonephritis in renal allograft related to antibody-mediated rejection: A case report and literature review. Takahashi K; Malinzak LE; Safwan M; Kim DY; Patel AK; Denny JE Transpl Infect Dis; 2019 Feb; 21(1):e13026. PubMed ID: 30414224 [TBL] [Abstract][Full Text] [Related]
40. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Kedainis RL; Koch MJ; Brennan DC; Liapis H Am J Transplant; 2009 Apr; 9(4):812-9. PubMed ID: 19344468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]